MH
Risk Factors for Malignant Hyperthermia
1 in 100,000 surgical procedures in adults. 1 in 30,000 surgeries in children. Basically, more common in children.
Key risk factors include:
Family history of MH
Young boys (Children under 15 years comprise 52% of all reactions)
Geographic location impacts risk: Wisconsin, Nebraska, West Virginia, Michigan
Pathophysiology of MH
Inherited, autosomal dominant disorder affecting skeletal muscle characterized by impaired regulation and maintenance of calcium levels.
**non-depolarizers are not the best choice for tx as you are not treating the main cause.
Associated with 34 genetic mutations primarily linked to the RYR1 (ryanodine) gene.
The RYR1 gene encodes the ryanodine receptor, the major calcium release channel. Defective ryanodine receptors lead to excessive calcium release from the sarcoplasmic reticulum (sarcolemma) into the cell.
The SERCA2 pump's attempt to return excess calcium to the sarcoplasmic reticulum.
Breakdown of the sarcolemma allows potassium and myoglobin (toxic to kidneys) to enter systemic circulation (Aka, rhabdomyolysis occurs).
Summary: Massive outflow Ca —> sustained muscle contraction —> hypermetabolism (as the body tries to pump it back into the cell) —> sarcolemma de-stability (cell membrane failure) —> myoglobin/potassium leakage —> Cardiac arrest
Summary: Consequences of excessive intracellular calcium:
Increased muscle rigidity due to sustained contractions.
Increased oxygen consumption
Increased metabolic rate (hypermetabolism) and rapid ATP depletion.
Increased CO₂ and heat production.
Overall: respiratory + lactic acidosis
**can occur even hours after surgery. You can differentiate from other neuroleptic disorders bc NMBDs will not resolve s/s.
S/S of MH
**Unexplained, sudden rise in end tidal CO₂ >55 mm Hg (which cannot be treated by increasing RR)
Unexplained tachycardia or arrythmias (cardiac arrest likely d/t hyperkalemia)
Masseter muscle or generalized muscle rigidity.
Rising patient temperature (late sign)
Cola-colored urine (myoglobinuria).
Mottled, cyanotic skin.
Decreased oxygen saturation (Sao2).
Tachypnea.
Labile blood pressure
Laboratory Findings
Arterial blood gases indicate respiratory and metabolic acidosis.
Serum potassium levels >6 mEq/L.
Creatine kinase levels >20,000 units/L.
Serum myoglobin >170 mcg/L.
Urine myoglobin >60 mcg/L.
MH Triggering Agents
The two main categories are Volatile anesthetics and Succinylcholine
TIVA and N2O does NOT cause MH
Preparation for MH Susceptible Patients
Conduct a thorough preoperative evaluation to identify risks:
Family history of unexpected complications, high fever, or death.
hx of muscle rigidity under anesthesia.
Dark-colored urine after exercise or surgery.
Hx of central core disease, King Denborough syndrome, or multi mini core disease.
Consider alternatives to general anesthesia: Regional and TIVA anesthetics.
Remove any trace has from the machine (even if not using!):
Change CO₂ absorbent.
Remove or tape off vaporizers.
Flush the machine with a new circuit and fresh gas flows exceeding 10 L/min for 20-90 minutes
Apply charcoal filters.
Treatment for MH
Immediate actions:
#1: Discontinue the triggering agent. Use an ambu bag until the entire circuit is changed out.
Remember that MH is a self-sustaining chemical reaction, so it must be reversed!
Call for help and utilize the MH crisis hotline.
Medication protocol:
Administer Dantrolene at a dose of 2.5 mg/kg, repeating every 5-10 minutes until symptoms cease.
Continuation of Dantrolene in ICU for a minimum of 24 hours at 1 mg/kg every 4 hours as a bolus or 0.25 mg/kg/hr for continuous infusion.
Hyperventilation with 100% oxygen at flows >10L/min to improve oxygenation and decrease CO₂ levels.
Laboratory tests required: Coagulation profile, ABGs, electrolytes, CK, and myoglobin and liver enzymes.
Cooling of the patient: Administer IV fluids and apply ice packs to the groin, axilla, and neck. However, stop cooling at 38 C to prevent hypothermia
Tx arrhythmias: Avoid calcium channel blockers. You can use amio if needed.
CCBs such as verapamil can further cause hyperkalemia if given to a patient who also received dantrolene!
Treatment for hyperkalemia: hyperventilation, bicarbonate (1-2 mEq/kg), intravenous insulin/glucose, calcium chloride (10 mg/kg), albuterol, diuresis
Maintain hydration with a urine output goal of >1 ml/kg/hour (d/t rhabdo effects)
Dantrolene (Dantrium/Revonto) or Ryanodex Medications for MH
MOA: Acts directly on skeletal muscle by Binding to ryanodine receptors to inhibit calcium efflux from the sarcoplasmic reticulum
Tip: treat as quickly as possible because it is a rapid biochemical crisis where seconds = muscle cells dying
MHAUS recommends either drug version to be immediately available at all times:
Dantrolene (Dantrium/Revonto): 20 mg vials, stocked to a minimum of 36 vials. Each bottle contains 3 g of mannitol and must be diluted with 60 ml of sterile WATER, shaken vigorously until clear due to poor solubility (very hard to mix together).
**mannitol is added for 1) diuresis effects since pt will have rhabdomyolsis and 2) increase solubility of the dantrolene powder to try and help make it more mixable with liquid
Ryanodex is 250 mg vial, stocked to minimum of x3 vials (MUCH more expensive). Each bottles contains 0.125 g mannitol and must be diluted with 5 mL of sterile WATER. A little easier to mix than dantrolene, but still hard.
Adverse effects of dantrolene:
Muscle weakness.
Hepatotoxicity.
CNS depression.
Myocardial depression.
Diagnostic Testing for MH
The most accurate and accepted test is the Caffeine Halothane Contracture Test (CHCT).
Availability: Only at 5 medical centers in North America.
Costs: $6,000 or more, and insurance may not cover it.
Patients must travel to testing centers as the muscle biopsy needs to be fresh.
Genetic testing for RYR1, CACNA1S, or STAC3 gene mutations is a less expensive alternative but has lower accuracy.